Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape

BackgroundFailure on Highly Active Anti-Retroviral Treatment is often accompanied with development of antiviral resistance to one or more drugs included in the treatment. In general, the virus is more likely to develop resistance to drugs with a lower genetic barrier. Previously, we developed a method to reverse engineer, from clinical sequence data, a fitness landscape experienced by HIV-1 under nelfinavir (NFV) treatment. By simulation of evolution over this landscape, the individualized genetic barrier to NFV resistance may be estimated for an isolate.ResultsWe investigated the association of estimated genetic barrier with risk of development of NFV resistance at virological failure, in 201 patients that were predicted fully susceptible to NFV at baseline, and found that a higher estimated genetic barrier was indeed associated with lower odds for development of resistance at failure (OR 0.62 (0.45 - 0.94), per additional mutation needed, p = .02).ConclusionsThus, variation in individualized genetic barrier to NFV resistance may impact effective treatment options available after treatment failure. If similar results apply for other drugs, then estimated genetic barrier may be a new clinical tool for choice of treatment regimen, which allows consideration of available treatment options after virological failure.

[1]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[2]  Matthew J. Gonzales,et al.  Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..

[3]  Rami Kantor,et al.  Drug resistance in non-subtype B HIV-1. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  Dan Turner,et al.  Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2005, Antimicrobial Agents and Chemotherapy.

[5]  Julio S. G. Montaner,et al.  HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort , 2001, AIDS.

[6]  Guy Burtonboy,et al.  Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor , 2001, Antimicrobial Agents and Chemotherapy.

[7]  Valentina Svicher,et al.  Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[8]  Dan Turner,et al.  Variability in the PR and RT Genes of HIV-1 Isolated from Recently Infected Subjects , 2004, Antiviral chemistry & chemotherapy.

[9]  K. Crandall,et al.  The causes and consequences of HIV evolution , 2004, Nature Reviews Genetics.

[10]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[11]  Yves Moreau,et al.  Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response , 2008, Antiviral therapy.

[12]  Anne-Mieke Vandamme,et al.  Investigation of Baseline Susceptibility to Protease Inhibitors in HIV-1 Subtypes C, F, G and Crf02_Ag , 2005, Antiviral therapy.

[13]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[14]  Yves Moreau,et al.  Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment , 2008, Bioinform..

[15]  A. Vandamme,et al.  A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients , 2001, Antiviral therapy.

[16]  R. Harrigan,et al.  Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies , 2000, AIDS.

[17]  JD Lundgren,et al.  Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.

[18]  BMC Bioinformatics , 2005 .

[19]  Yves Moreau,et al.  Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance , 2006, Bioinform..

[20]  Deenan Pillay,et al.  Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[21]  Klaus Korn,et al.  The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes , 2006, Journal of acquired immune deficiency syndromes.

[22]  Robert Shafer,et al.  HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed , 1999, Annals of Internal Medicine.

[23]  Jonathan M. Schapiro,et al.  Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.

[24]  Amalio Telenti,et al.  Update of the drug resistance mutations in HIV-1: Fall 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[25]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[26]  Alessandro Cozzi-Lepri,et al.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy , 2004, AIDS.

[27]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[28]  P Pezzotti,et al.  Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. , 2001, The Journal of infectious diseases.

[29]  Anne-Mieke Vandamme,et al.  Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G , 2005, AIDS.